Placeholder Banner

Statement Regarding Interactions With Healthcare Professionals

February 19, 2009

Statement regarding Interactions with Healthcare Professionals

BIO and our member companies remain dedicated to the improvement of patient care and the advancement of medical science.  In pursuing this mission, we recognize that adherence to strict ethical standards and compliance with applicable laws is critical to our industry’s ability to continue our collaboration with healthcare professionals and maintain the trust of our patients.  For these reasons, BIO supports the principles in PhRMA’s Code governing interactions with healthcare professionals, and will continue to encourage its members to maintain the highest standards for ethical business practices and socially responsible industry conduct related to company interactions with healthcare professionals.

Specifically, BIO encourages each of its member companies that are involved in the marketing of biologics or other pharmaceuticals to United States healthcare professionals to adopt a transparent and rigorous code of conduct, such as the PhRMA Code, tailored as appropriate to its own particular circumstances and which also ensures compliance with all applicable local, state, and federal laws and regulations.  BIO members that wish to sign on to the PhRMA Code may do so, even if they are not PhRMA members.

 

Discover More
John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary leadership of Dr. Peter Marks, the FDA…
WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90…
WASHINGTON D.C. – Today, the Biotechnology Innovation Organization (BIO), in partnership with Kearney, a global management consulting firm, released a first-of-its-kind report that assesses the significant economic impact of the U.S. bioeconomy…